La cadena de opciones muestra datos clave de las opciones de acciones de Monte Rosa Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Monte Rosa Therapeutics..

Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa, Cadena de Opciones

Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics Inc

WIIM

BEAM

Beam Therapeutics shares are trading lower after the company announced a $500 million offering.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agilent.com&amp;esheet=54221636&amp;newsitemid=20250310422488&amp;lan=en-US&amp;anchor=Agilent+Technologies+Inc.&amp;index=1&amp;md5=50a85d0a34fe29942381dfb2eefc68af">Agilent Technologies Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) today announced its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen%2Fproduct%2Fpharmdx%2Fpd-l1-ihc-28-8-pharmdx%2Fpd-l1-ihc-28-8-pharmdx-for-autostainer-link-48-153940&amp;esheet=54221636&amp;newsitemid=20250310422488&amp;lan=en-US&amp;anchor=PD-L1+IHC+28-8+pharmDx&amp;index=2&amp;md5=72c49e2091ba654aa1fc5cd98448661f">PD-L1 IHC 28-8 pharmDx</a> kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen%2Fproduct%2Fautostainer-link-solution-for-ihc%2Fautostainer-link-48%2Fautostainer-link-48-75845&amp;esheet=54221636&amp;newsitemid=20250310422488&amp;lan=en-US&amp;anchor=Agilent+Autostainer+Link+48&amp;index=3&amp;md5=7be86c60dabca2090227a31e606801cc">Agilent Autostainer Link 48</a> advanced staining solution.
Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accounting for over two million new cases in 2020 and an estimated 1.77 million deaths each year, and malignant melanoma accounting for over 324,000 new cases in 2020 and over 57,000 deaths each year2. PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.
When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be eligible for treatment with Bristol Myers Squibb's OPDIVO&#xAE; (nivolumab) in combination with platinum based chemotherapy; and (b) patients 12 years of age and older with tumor cell PD-L1 expression &lt; 1% that have previously untreated advanced (metastatic or unresectable) melanoma may be eligible for treatment with Bristol Myers Squibb's Opdualag&#x2122; (nivolumab and relatlimab).
PD-L1 IHC 28-8 pharmDx is the only clinically validated test for identifying patients for these treatments; these two new indications will aid pathologists, in conjunction with oncologists, in selecting appropriate treatment options, offering hope for patients diagnosed with these cancers. IVDR compliance certification further enhances the confidence of patients, consumers, and healthcare professionals in the EU by demonstrating that these medical devices can be safely relied upon as part of the diagnostic workflow.

Biotech

News

General

Agilent PD-L1 IHC 28-8 PharmDx Receives EU IVDR Certification As A Companion Diagnostic Test For Non-small Cell Lung Cancer And Melanoma Indications

Barrington Research analyst Vincent Colicchio maintains Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) with a Outperform and maintains $3.75 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Information Servs Gr, Maintains $3.75 Price Target

U.S. stock futures were lower this morning, with the Dow futures falling around 1% on Monday.
Shares of Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) fell sharply in today's pre-market trading after the company announced it will acquire Redfin in an all-stock transaction <a href="https://www.benzinga.com/quote/RKT/news">valued at $12.50 per share</a>.
Rocket Companies shares dipped 11% to $14.04 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares dipped 9.2% to $7.95 in pre-market trading. Intuitive Machines shares fell 22% on Friday after the company&#8217;s lander experienced technical issues.</li>
<li>Health In Tech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>) fell 8.1% to $6.57 in pre-market trading. Health In Tech will announce fourth quarter and full year 2024 financial results on March 17, 2025.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) dipped 8.2% to $248.25 in pre-market trading.</li>
<li>Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) fell 7.6% to $3.92 in pre-market trading.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) tumbled 6.3% to $41.58 in pre-market trading.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 6.2% to $81.76 in pre-market trading after the company reported Phase 3 results for CagriSema, showing 15.7% weight loss over 68 weeks.</li>
<li>Eton Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) fell 2.3% to $14.25 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Markets

ETON

HOOD

LUNR

SFIX

Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BECN

Beacon Roofing Supply shares are trading higher after the company announced QXO may potentially acquire it for approximately $11 billion. Additionally, Beacon announced a strategic investment in Renovate Robotics for roofing automation.

PTGX

Protagonist Therapeutics shares are trading higher after the company announced topline results from its Phase 2b ANTHEM-UC study of icotrokinra in ulcerative colitis. The study met its primary endpoint in all dose groups evaluated.

The U.S. shale sector is capable of ramping up&nbsp;oil production even if prices&nbsp;fall to $50 per barrel, according to&nbsp;U.S. Energy Secretary, Chris Wright.&nbsp;
What Happened: Wright, formerly the CEO of Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>), is optimistic about the sector&#8217;s potential to innovate and achieve efficiency gains, thereby enabling higher production at lower prices, <a href="https://www.ft.com/content/6b7f0af8-6c59-44bb-b07a-43d4768b96fd?">reported</a> The Financial Times. 
He said that they were going to see the same kind of market dynamics at that time. He explained that new supply would drive prices down, companies would innovate and lower their prices, and consumers and suppliers would fluctuate between options.
the U.S. shale sector is well-positioned to fulfill Donald Trump's call to &#8220;drill, baby, drill,&#8221; he added.
However, he anticipates an industry disruption similar to the 2014 price war between OPEC producers and the shale industry. "There were a lot of bankruptcies. There was a lot of disruption, but the end result was far lower costs to produce a barrel of oil," Wright told the publication.
A lot of U.S. oil executives are likely to disagree with Wright&#8217;s remarks amid fear that lower oil prices could reduce profits and force cutbacks in drilling activity, despite President Trump&#8217;s push for increased production.
SEE ALSO: <a href="https://www.benzinga.com/markets/equities/25/03/44160535/exxonmobil-and-qatarenergys-golden-pass-lng-project-gets-extended-export-permit-from-us-energy-department">ExxonMobil And QatarEnergy&#8217;s Golden Pass LNG Project Gets Extended Export Permit From US Energy Department</a>
Why It Matters: This statement comes after a sharp decline in oil prices, with Brent crude dropping below $70 last week for only the third time since Russia&#8217;s full-scale invasion of Ukraine in 2022. The recent decline in oil prices has been influenced by several factors, including trade policies and OPEC+ production increases.
In March 2025, West Texas Intermediate crude oil prices fell 6% to reach multi-year lows. President Trump&#8217;s 25% tariff on energy imports from Canada and Mexico disrupted trade flows and raised <a href="https://www.benzinga.com/25/03/44168987/oil-prices-hit-multi-year-lows">concerns about slower </a>global growth and reduced energy demand.
Award-winning energy historian, Daniel Yergin told the Financial Times, "at $50 a barrel the economics of shale don't work.&#8221; 
Furthermore, Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) warned that a proposed 10% U.S. oil tariff could lead to a $10 billion annual loss for foreign producers, posing a significant threat to Canadian and Latin American <a href="https://in.benzinga.com/markets/commodities/25/02/43900287/trumps-10-oil-tariff-could-deal-10-billion-annual-blow-to-canada-and-other-foreign-producers-goldman-sachs-warns">heavy crude suppliers</a> that depend on U.S. refiners. 
Noble Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) plunged over 22% during the last 30 days to close at $24.71 on Friday, while Western Midstream Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) declined 4.07% during the same period.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/03/44211191/vp-vance-slams-pro-ukraine-protesters-for-confronting-him-with-his-daughter-chasing-a-three-year-old-for-politics">VP Vance Slams Pro-Ukraine Protesters for Confronting Him With His Daughter: &#8216;Chasing a Three-Year-Old for Politics&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

LBRT

US Shale Industry Can Deliver Trump's Pledge For 'Drill, Baby, Drill' Despite Falling Prices, Says Energy Secretary: 'The Economics Of Shale Don't Work,' Says Expert

Protagonist Says All Three Doses Met The Primary Endpoint Of Clinical Response At Week 12, With A Favorable Safety Profile

Cohen &amp; Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COHN#AMEX">COHN</a>) reported quarterly losses of $(1.32) per share. This is a 145.83 percent decrease over earnings of $2.88 per share from the same period last year. The company reported $18.54 million in sales this quarter. This is a 46.20 percent decrease over sales of $34.46 million the same period last year.

Earnings

COHN

Cohen & Co Q4 Adj EPS  $(1.32) Down From $2.88 YoY, Sales $18.54M Down From $34.46M YoY

Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28
All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety profile
These results in ulcerative colitis build on strong data recently reported for the plaque psoriasis Phase 3 program
NEWARK, CALIFORNIA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / March 10, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study conducted by Protagonist's collaboration partner, Johnson &amp; Johnson, met its primary endpoint of clinical responsea in all icotrokinra dose groups evaluated. Additionally, the study demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remissionb, symptomatic remission and endoscopic improvement at Week 12.
Key findings from the ANTHEM-UC study (n=252) are summarized below:
All three doses of once daily icotrokinra met the primary endpoint of clinical response at Week 12.
A response rate of 63.5% for patients treated with the highest dose of icotrokinra was achieved at Week 12 versus 27.0% for placebo (p&lt;0.001).
30.2% of patients treated with the highest dose of icotrokinra demonstrated clinical remission at Week 12 versus 11.1% of patients who received placebo (p&lt;0.001).
Clinical remission and response rates continued to improve through Week 28.i
Icotrokinra was well tolerated with the proportions of participants reporting one or more adverse events (AEs) being similar between the icotrokinra dose groups and the placebo group.i

Protagonist Reports Top Line Results From Phase 2b Study Of Icotrokinra Showing Potential To Transform The Treatment Paradigm For Patients With Ulcerative Colitis; Clinical Response Rate Of 63.5% And Clinical Remission Rate Of 30.2% Achieved At Week 12 With The Highest Dose, Which Continued To Improve Through Week 28

Syntec Optics Holdings, Inc. ("Syntec Optics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>), a leading provider of mission-critical products to advanced technology defense, biomedical, and communications equipment manufacturers, today announced its continued collaboration to enable development of a novel photonic biosensing technology poised to transform drug discovery and testing.
Syntec Optics is providing critical optical manufacturing and sub-assembly processes to image laser light into our OEM's photonic integrated circuits (PICs), enabling the integration of photonic sensors into micro physiological systems (MPS). Scientists can now observe how human cells respond to drugs in real time, significantly improving the accuracy and speed of drug development.
Our OEM's groundbreaking approach addresses the critical challenge of high drug failure rates in clinical trials. Traditional testing methods often fail to predict human responses accurately. By replacing current animal models and lab tests with precise, real-time photonic biosensing, development timelines can be accelerated, and clinical trial costs can be lowered.

OPTX

Syntec Optics Announces Its Continued Collaboration On Novel Photonic Biosensing Technology For Drug Discovery, Aiming To Improve Testing Accuracy And Speed By Integrating Photonic Sensors Into Micro Physiological Systems, Addressing High Drug Failure Rates In Clinical Trials

MSTR

MicroStrategy shares are trading lower after the company announced a $21 billion at-the-market offering program to issue and sell Series A preferred stock.

D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and maintains $21 price target.

TRVI

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) ("Gorilla" or the "Company") announced it has formally launched the initial phases of Thailand's largest-ever AI-driven energy transformation initiative with Thailand's Provincial Electricity Authority (the "Electricity Authority"). This significant moment took place in the presence of representatives of the Electricity Authority and representatives of the British Government, underscoring the global importance of this transformation.
This $1.8 billion initiative, spanning the next 15 years, is expected to digitally modernize Thailand's power infrastructure through AI, automation, and cybersecurity, ensuring greater efficiency, security, and sustainability. With this formal agreement, Gorilla and the Electricity Authority are now progressing into the structured definition phase, where the foundational scope, deployment strategies and operational frameworks will be developed.

GRRR

Gorilla Technology Says $1.8B Initiative, Spanning The Next 15-Years, Is Expected To Digitally Modernize Thailand's Power Infrastructure Through AI, Automation, And Cybersecurity, Ensuring Greater Efficiency, Security, And Sustainability

Gorilla Technology  Launches The Initial Phases Of Thailand's Largest-ever AI-driven Energy Transformation Initiative With Thailand's Provincial Electricity Authority

Board Reaffirms Recommendation that Shareholders Vote in Favor of Aptean Transaction
Logility Supply Chain Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) ("Logility" or the "Company"), a leader in AI-first supply chain management software, today announced that the unsolicited non-binding proposal to acquire all outstanding shares of Logility's common stock, previously announced on March 7, 2025 (the "Unsolicited Proposal"), has been withdrawn by the bidder. As a result, Logility has ceased discussions with the bidder regarding the Unsolicited Proposal.
Logility's definitive agreement to be acquired by Aptean, Inc. ("Aptean") for $14.30 per share in an all-cash transaction remains in full force and effect. The Logility Board of Directors reaffirms its existing recommendation that Logility's shareholders vote in favor of the transaction with Aptean.

Asset Sales

LGTY

Logility Maintains Recommendation For Shareholders To Support $14.30 Per Share Acquisition By Aptean After Unsolicited Non-Binding Proposal  Withdrawal

AMRK

A-Mark Precious Metals Acquires Stack's Bowers Galleries For $92M; Acquires AMS Holding For $50.0M; Acquires Pinehurst Coin Exchange For $6.5M

SenesTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>, ", SenesTech", or the ", Company", ))), a pioneer in fertility control solutions for managing rodent populations, announced today the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 374,718 shares of the Company's common stock originally issued by the Company on August 23, 2024, each having an original exercise price of $4.35 per share, at a reduced exercise price of $2.90 per share. In addition, the Company will issue new short-term warrants, as described below. The closing of the warrant exercise transaction is expected to occur on or about March 11, 2025, subject to Stockholder Approval (as defined herein) and satisfaction of customary closing conditions.
H.C. Wainwright is acting as the exclusive placement agent for the transaction.
The aggregate gross proceeds from the exercise of the existing warrants are expected to be approximately $1.1 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential gross proceeds from the new short-term warrants, if fully exercised on a cash basis, will be approximately $4.3 million. No assurance can be given that any of the new short-term warrants will be exercised. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.
The resale of the shares of common stock issuable upon the exercise of the existing warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-282286).

Offerings

SNES

SenesTech Announces Entry Into Definitive Agreements For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 374,718 Shares Of Common Stock, Each Having An Original Exercise Price Of $4.35 Per Share, At A Reduced Exercise Price Of $2.90 Per Share For Gross Proceeds Of $1.1M

Management

Service Properties Trust Appoints Chris Bilotto As A Managing Trustee, President And Chief Executive Officer, Effective March 10, 2025

Strategy expects to make sales of perpetual strike preferred stock pursuant to the ATM Program in a disciplined manner over an extended period, taking into account the trading price and trading volumes of the perpetual strike preferred stock at the time of sale.
Strategy intends to use the net proceeds from the ATM Program for general corporate purposes, including the acquisition of bitcoin and for working capital.

STRK

Strategy Announces $21B STRK At-The-Market Program

Press Releases

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Health Care

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Comments

Monte Rosa Therapeutics

Monte Rosa Therapeutics (GLUE) Opciones

Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL